Recent findings highlight wide-ranging differences in use of dermatologic care in the US across various demographic and socioeconomic lines. Researchers conducted a retrospective analysis of nationally representative data from the 2007 to 2015 Medical Expenditure Panel Survey (MEPS) (n=183,054). Health care use outcomes for dermatologic conditions were examined via multivariable logistic regression analyses of outpatient and office-based dermatologist visit rates accounting for sex, age, race/ethnicity, educational level, income, insurance status, region, self-reported condition, and self-reported health status. They found:
- Of total MEPS respondents (mean [SD] age, 34  years; 52.1% female), 19,561 (10.7%) self-reported a dermatologic condition; 9,645 patients had a total of 11,761 outpatient visits to dermatologists.
- Hispanic and black patients were both less likely to receive outpatient care for their dermatologic condition relative to non-Hispanic white patients.
- Male patients were less likely to receive outpatient dermatologic care than female patients, and Midwestern patients were less likely to receive outpatient dermatologic care than Northeastern patients.
- Patients with Medicaid or Medicare coverage and uninsured patients were both less likely to receive outpatient dermatologic care than privately insured patients.
Tripathi R, Knusel KD, Ezaldein HH, Scott JF, Bordeaux JS. Association of demographic and socioeconomic characteristics with differences in use of outpatient dermatology services in the United States. [Published online ahead of print September 26, 2018]. JAMA Dermatology. doi:10.1001/jamadermatol.2018.3114.
This Week's Must Reads
Link Between AD and Autoimmune Disorders, J Am Acad Dermatol; ePub 2018 Oct 1; Narla, et al
Predictors of Mucosal Melanoma Survival, J Am Acad Dermatol; ePub 2018 Oct 5; Altieri, et al
Prevalence of Acne Vulgaris Among Patients with HS, J Am Acad Dermatol; ePub 2018 Oct 1; Wertenteil, et al
Skin Disease Epidemiology in a Diverse Population, J Drugs Dermatol; 2018 Oct; Gaulding, et al
Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8